Olopatadine 0.6% nasal spray protects from vasomotor challenge in patients with severe vasomotor rhinitis

18Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Vasomotor rhinitis (VMR) is a hypersensitivity syndrome with heightened reactivity to environmental triggers. Methods: Twenty-two patients with severe VMR were treated nasally with either normal saline or 0.6% olopatadine and challenged nasally with a hyperosmolar mannitol solution. Results: Treatment with 0.6% olopatadine resulted in an improvement in instantaneous nasal symptom scores at 5 and 30 minutes (p < 0.01) compared with baseline and at 30 minutes after hyperosmolar challenge compared with saline-pretreated individuals (p < 0.01). There was also an improvement in nasal peak inspiratory flow rate at 30 minutes after hyperosmolar challenge compared with saline-pretreated individuals (p < 0.01). Conclusion: In this patient population 0.6% olopatadine appears to be efficacious in symptom reduction in VMR and protects from hyperosmolar challenge. Copyright © 2011, OceanSide Publications, Inc.

Cite

CITATION STYLE

APA

Smith, P. K., & Collins, J. (2011). Olopatadine 0.6% nasal spray protects from vasomotor challenge in patients with severe vasomotor rhinitis. American Journal of Rhinology and Allergy, 25(4). https://doi.org/10.2500/ajra.2011.25.3620

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free